<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03037411</url>
  </required_header>
  <id_info>
    <org_study_id>S2346</org_study_id>
    <nct_id>NCT03037411</nct_id>
  </id_info>
  <brief_title>A Real World Evaluation of the ELUVIA Stent in Subjects With Lesions Located in the Femoropopliteal Arteries</brief_title>
  <acronym>REGAL</acronym>
  <official_title>A Real World Evaluation of the ELUVIA Drug Eluting Stent in All-Comers With Superficial Femoral Artery and Proximal Popliteal Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The REGAL study is a European, prospective, multi-center Post-Market Clinical Follow-up
      (PMCF) trial providing additional data including health economics data to support the use of
      the ELUVIA stent in the treatment of lesions located in the femoropopliteal arteries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A European, prospective, multi-center Post-Market Clinical Follow-up (PMCF) trial providing
      additional data including health economics data to support the use of the ELUVIA stent in the
      treatment of lesions located in the femoropopliteal arteries.

      The objective of the study is to collect additional data including health economics data to
      support the use of the ELUVIA Drug-Eluting Vascular Stent System (ELUVIA Stent) for treating
      Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA) lesions.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Health care costs</measure>
    <time_frame>Index Procedure, 1, 6, 12 and 24 months</time_frame>
    <description>Health care costs at index procedure and changes in health care costs from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Improvement</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Change in EQ-5D-5Lâ„¢ from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Walking Improvement</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Change in Walking Impairment Questionnaire (WIQ) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Primary and Secondary Sustained Clinical Improvement</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Changes in Rutherford Classification from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Hemodynamic Improvement</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Changes in in Ankle-Brachial Index (ABI) from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health care utilization</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Changes in healthcare utilization over time</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Technical success of the stenting procedure</measure>
    <time_frame>During stenting procedure</time_frame>
    <description>Technical success defined as delivery and deployment of the study stent to the target lesion to achieve residual angiographic stenosis no greater than 30% assessed visually</description>
  </other_outcome>
  <other_outcome>
    <measure>Procedural success of the stenting procedure</measure>
    <time_frame>within 24 hours of stenting procedure</time_frame>
    <description>Procedural success defined as technical success with no MAEs noted within 24 hours of the stenting procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Event and Major Adverse Event (MAE) rate</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Adverse Event rate and MAE rate, defined as all causes of death, target limb major amputation and/or Target Lesion Revascularization rate at each time point</description>
  </other_outcome>
  <other_outcome>
    <measure>Primary patency</measure>
    <time_frame>6, 12 and 24 months</time_frame>
    <description>Primary patency of target lesion assessed by duplex ultrasound as adjudicated by an independent core laboratory</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically-driven Target Lesion Revascularization (TLR) Rate</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Target Lesion Revascularization is defined as any surgical or percutaneous intervention to the target lesion(s) after the stenting procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Clinically-driven Target Vessel Revascularization (TVR) Rate</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Target Vessel Revascularization is defined as any surgical or percutaneous intervention to the target vessel after the stenting procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Distribution of Rutherford Classification</measure>
    <time_frame>1, 6, 12 and 24 months</time_frame>
    <description>Rutherford Classification:
0 Asymptomatic - Normal Treadmill /stress test
Mild claudication - Completes treadmill exercise; ankle pressure (AP) after exercise &lt;50mm Hg, but &gt;25 mm Hg less than BP
Moderate claudication - Between categories 1 and 3
Severe claudication - Cannot complete treadmill exercise and AP after exercise &lt;50 mm Hg
Ischemic rest pain - Resting AP &lt;40 mm Hg, flat or barely pulsatile ankle or metatarsal pulse volume recording (PVR); toe pressure (TP) &lt;30 mm Hg
Minor tissue loss-nonhealing ulcer, focal gangrene with diffuse pedal edema - Resting AP &lt;60 mm Hg, ankle or metatarsal (MT) PVR flat or barely pulsatile; TP &lt;40 mm Hg
Major tissue loss-extending above MT level - Same as Category 5</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Arterial Occlusive Diseases</condition>
  <condition>Atherosclerosis</condition>
  <condition>Vascular Diseases</condition>
  <condition>Arteriosclerosis</condition>
  <arm_group>
    <arm_group_label>ELUVIA stent implantation</arm_group_label>
    <description>Peripheral stenting</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Peripheral stenting</intervention_name>
    <description>stent implantation during the index procedure</description>
    <arm_group_label>ELUVIA stent implantation</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The Intended population for the REGAL study are 'real world'-patients with symptomatic
        de-novo, restenotic, or (re)occluded lesions in the native superficial femoral artery (SFA)
        and/or proximal popliteal artery with reference vessel diameter (RVD) ranging from 4.0-6.0
        mm, suitable for endovascular treatment.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects age 18 and older

          2. Subject is willing and able to provide written consent before any study-specific test
             or procedure is performed and agrees to attend all follow-up visits

          3. De novo, restenotic or (re)occluded lesions in the native femoro-popliteal arteries,
             with reference vessel diameter (RVD) ranging from 4.0-6.0 mm, suitable for
             endovascular treatment

        Exclusion Criteria:

          1. Subject is pregnant or planning to become pregnant during the course of the study

          2. Life expectancy of less than 1 year (which is defined as documented life expectancy
             less than 12 months due to other medical co-morbid condition(s) that could limit the
             subject's ability to participate in the clinical follow-up, limit the subject's
             compliance with the standard of care follow-up, or impact the scientific integrity of
             the trial)

          3. Known allergy to the ELUVIA stent system or any of its components, concomitant
             medication, contrast agents (that cannot be medically managed)

          4. Subject enrolled in an investigational study that has not reached primary endpoint at
             the time of enrollment or that clinically interferes with the current study
             assessments (Note: studies requiring extended follow-up for products that were
             investigational, but have become commercially available since then are not considered
             investigational studies)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlo Setacci</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinico Le Scotte, Siena</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Evi Petro</last_name>
    <phone>+3232900306</phone>
    <email>evi.petro@genae.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angela Schutt</last_name>
    <phone>+17634942166</phone>
    <email>Angela.Schutt@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische UniversitÃ¤t Graz</name>
      <address>
        <city>Graz</city>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marianne Brodmann, MD</last_name>
      <email>marianne.brodmann@medunigraz.at</email>
    </contact>
    <investigator>
      <last_name>Marianne Brodmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZOL Genk</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Herman SchroÃ«, MD</last_name>
      <email>Herman.Schroe@ZOL.BE</email>
    </contact>
    <investigator>
      <last_name>Herman SchroÃ«, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Heilig Hart Tienen</name>
      <address>
        <city>Tienen</city>
        <state>Vlaams-Brabant</state>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koen Keirse, MD</last_name>
      <email>koen.keirse@rztienen.be</email>
    </contact>
    <investigator>
      <last_name>Koen Keirse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Grenoble-Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Augustin Pirvu, MD</last_name>
      <email>APirvu@chu-grenoble.fr</email>
    </contact>
    <investigator>
      <last_name>Augustin Pirvu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Parly II</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgio Angelopoulos, MD</last_name>
      <email>giorginos78@msn.com</email>
    </contact>
    <investigator>
      <last_name>Georgio Angelopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASL Asti</name>
      <address>
        <city>Asti</city>
        <zip>14100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Gaggiano, MD</last_name>
      <email>agaggiano@libero.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Gaggiano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierfrancesco Veroux, MD</last_name>
      <email>pveroux@unict.it</email>
    </contact>
    <investigator>
      <last_name>Pierfrancesco Veroux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico di Monza</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Scalise, MD</last_name>
      <email>filippo.scalise@policlinicodimonza.it</email>
    </contact>
    <investigator>
      <last_name>Filippo Scalise, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesco Speziale, MD</last_name>
      <email>francesco.speziale@uniroma1.it</email>
    </contact>
    <investigator>
      <last_name>Francesco Speziale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>L'Azienda sanitaira ASL Roma 1</name>
      <address>
        <city>Roma</city>
        <zip>00193</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Ronchey, MD</last_name>
      <email>sonia.ronchey@aslroma1.it</email>
    </contact>
    <investigator>
      <last_name>Sonia Ronchey, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Nano, MD</last_name>
      <email>giovanni.nano@libero.it</email>
    </contact>
    <investigator>
      <last_name>Giovanni Nano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Azienda Ospedaliera Universitaria Senese</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domenico Benevento, MD</last_name>
      <email>d.benevento@ao-siena.toscana.it</email>
    </contact>
    <investigator>
      <last_name>Domenico Benevento, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ignacio Agundez, MD</last_name>
      <email>nachez1967@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ignacio Agundez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hosp. Puerta del Mar</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Rodriguez PiÃ±ero, MD</last_name>
      <email>manuel.rodriguez.pinero.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Manuel Rodriguez PiÃ±ero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de AlcÃ¡ntara</name>
      <address>
        <city>CÃ¡ceres</city>
        <zip>10004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier FernÃ¡ndez Portales, MD</last_name>
      <email>portales70@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Javier FernÃ¡ndez Portales, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hosp . Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mercedes Guerra Requena, MD</last_name>
      <email>merguerra24@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mercedes Guerra Requena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hosp. Ntra Sra. del Rosario</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvador Sanchez Coll, MD</last_name>
      <email>ssanchezc@telefonica.net</email>
    </contact>
    <investigator>
      <last_name>Salvador Sanchez Coll, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isaac Martinez Lopez, MD</last_name>
      <email>isaacml20@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Isaac Martinez Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Madrid</city>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Maria Abadal, MD</last_name>
      <email>jmabadal@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Jose Maria Abadal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hosp. Complejo Hosp Universitario (CHUO)</name>
      <address>
        <city>Ourense</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nilo Mosquera, MD</last_name>
      <email>nmarochena@me.com</email>
    </contact>
    <investigator>
      <last_name>Nilo Mosquera, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de Montecelo (Pontevedra EOXI)</name>
      <address>
        <city>Pontevedra</city>
        <zip>30071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RaÃºl GarcÃ­a Casas, MD</last_name>
      <email>raulgc170@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>RaÃºl GarcÃ­a Casas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoni Gimenez Gaibar, MD</last_name>
      <email>agimenezg@tauli.cat</email>
    </contact>
    <investigator>
      <last_name>Antoni Gimenez Gaibar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foundation for the Aragonese Healthcare Research Institute</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JosÃ© Manuel Buisan-Bardaij</last_name>
    </contact>
    <investigator>
      <last_name>JosÃ© Manuel Buisan-Bardaij, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2016</study_first_submitted>
  <study_first_submitted_qc>January 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atherosclerosis</keyword>
  <keyword>Superficial Femoral Artery (SFA)</keyword>
  <keyword>Proximal Popliteal Artery (PPA)</keyword>
  <keyword>Stenting</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Health Economics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

